Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study HYPER-H21-2, which features LEXX’s patented DehydraTECH(TM)-processed cannabidiol (“CBD”), demonstrates up to a 23% decrease in blood pressure when compared to placebo. According to the announcement, partial results are being released today with additional blood pressure subset analyses, sleep quality and all other data analyses will be reported when complete. Partial results indicate that at selected times during the 24-hour study, volunteers with mild to moderate hypertension averaged as much as a 20 mmHg (i.e., 23%) decrease in BP relative to placebo, with volunteers averaging a notable reduction of 7.0% (p<0.001) in systolic pressure. In addition, over the same period, volunteers averaged a significant reduction of 5.3% (p<0.001) in MAP and a significant reduction of 3.5% in diastolic pressure relative to an increase in diastolic pressure (-0.8 vs. +2.7; p<0.001) from baseline with DehydraTECH-CBD relative to placebo treatment. The company noted that these numbers are particularly remarkable because many drugs currently used to treat hypertension require several weeks of treatment and/or combination dosing before they produce comparable results. Moving forward, Lexaria will evaluate the results of its first two human clinical hypertension studies before its upcoming pulmonary human clinical hypertension study of 2021 begins. “Over the initial 24 hours, Lexaria’s 2021 hypertension program is now delivering blood pressure reduction results competitive with — and in some cases even superior to — established oral pharmaceutical hypertension drugs,” said Lexaria CEO Chris Bunka in the press release. “DehydraTECH-CBD demonstrated a sustained and augmented effect upon blood pressure attenuation throughout the day, indicating effectiveness of the repeat dosing treatment schedule used in this study.”
To view the full press release, visit https://ibn.fm/mQ4ot
About Lexaria Bioscience Corp.
Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption of cannabinoids and nicotine by 5 to 10 times, and, in some instances with cannabinoids by as much as 27 times, compared to standard industry formulations, as well as reduce time of onset from one to two hours to minutes, and mask unwanted tastes. The delivery systems are also being evaluated for orally administered, anti-viral drugs, nonsteroidal, anti-inflammatory drugs (NSAIDs) and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
